TY - JOUR
T1 - Early treatment in HCV
T2 - is it a cost-utility option from the Italian perspective?
AU - Marcellusi, Andrea
AU - Viti, Raffaella
AU - Damele, Francesco
AU - Camma, Calogero
AU - Taliani, Gloria
AU - Mennini, Francesco Saverio
PY - 2016/8
Y1 - 2016/8
N2 - Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.
AB - Our model represents a tool for policy makers and health-care professionals, and provided information on the cost-utility of the early-treatment approach in HCV-infected patients in Italy. Starting innovative treatment regimens earlier keeps HCV-infected patients in better health and reduces the incidence of HCV-related events; generating a gain both in terms of health of the patients and correct resource allocation.
KW - Business and management studies
UR - http://www.ncbi.nlm.nih.gov/pubmed/27234943
U2 - 10.1007/s40261-016-0414-y
DO - 10.1007/s40261-016-0414-y
M3 - Article
C2 - 27234943
SN - 1173-2563
VL - 36
SP - 661
EP - 672
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
IS - 8
ER -